Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC).

Sumit K. Subudhi,Bilal A. Siddiqui,Joseph Maly,Lakshminarayanan Nandagopal,Elaine Tat Lam,Young E. Whang,Mukul Minocha,Vinita Gupta,Xianne Penny,Freda Cooner,Camila Jhones,Andrew Paluch,Mark Salvati,Margit Janat-Amsbury,Tobias Eggert,Hosein Kouros-Mehr,Anthony M. Joshua,Rahul Aggarwal,Johann S. de Bono

Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC).

2021

Sumit K. Subudhi
Bilal A. Siddiqui
Joseph Maly
Lakshminarayanan Nandagopal
Elaine Tat Lam
Young E. Whang
Mukul Minocha
Vinita Gupta
Xianne Penny
Freda Cooner
Camila Jhones
Andrew Paluch
Mark Salvati
Margit Janat-Amsbury
Tobias Eggert
Hosein Kouros-Mehr
Anthony M. Joshua
Rahul Aggarwal
Johann S. de Bono

TPS5088Background: Lesions in mCRPC are typically immunologically cold. AMG 160 binds to PSMA on cancer cells and CD3 on T cells, leading to T-cell infiltration, activation, expansion, and tumor ce...

Keywords:

Cancer research
Medicine
CD3
Glutamate carboxypeptidase II
infiltration
Cancer cell
castration resistant
immune therapy
Prostate cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations